Tracking pregnancy outcomes in women taking a nerve disease medication

This is a safety monitoring program for women who are pregnant or planning to become pregnant while taking patisiran, a medication used to treat hereditary transthyretin-mediated amyloidosis (a rare nerve disease). Researchers want to gather real-world information about how pregnancy progresses, any complications that occur, and the health of babies born to women exposed to this medication. This helps doctors understand whether the medication is safe to use during pregnancy.

When women with rare diseases need ongoing medication, doctors need good information about whether that medication might affect pregnancy or the developing baby. This program fills that gap by collecting and studying actual pregnancy experiences from women taking this medication.